Sequoia Financial Advisors LLC Has $1.59 Million Position in United Therapeutics Corporation $UTHR

Sequoia Financial Advisors LLC boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 83.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,271 shares of the biotechnology company’s stock after acquiring an additional 1,487 shares during the period. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $1,594,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC boosted its holdings in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia boosted its holdings in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a report on Thursday. Finally, Royal Bank Of Canada reduced their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Up 0.9%

Shares of NASDAQ:UTHR opened at $569.88 on Tuesday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company’s 50 day moving average price is $552.09 and its two-hundred day moving average price is $503.34. The firm has a market cap of $24.19 billion, a PE ratio of 21.04, a PEG ratio of 1.80 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. On average, research analysts expect that United Therapeutics Corporation will post 27.4 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 14,440 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 482,155 shares of company stock valued at $266,844,149 over the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.